Alamar Biosciences, Inc. (ALMR) vs NewAmsterdam Pharma Company N.V. (NAMS)
A side-by-side comparison of Alamar Biosciences, Inc. and NewAmsterdam Pharma Company N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALMR
Alamar Biosciences, Inc.
$34.50HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
NAMS
NewAmsterdam Pharma Company N.V.
$22.16HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — ALMR vs NAMS
growth of $100 · dividends reinvested · last 1yALMR +73.3% (+73.3%/yr)NAMS -34.3% (-34.3%/yr)ALMR compounded faster over this window
ALMR NAMS
ALMR vs NAMS: by the numbers
- •NAMS is the larger company ($2.59B vs $2.39B market cap).
- •Both run net losses; ALMR's is the smaller (-40.18% vs -3644.21% net margin).
Metrics side by side
Valuation
| Metric | ALMR | NAMS |
|---|---|---|
| P/S ratio | N/A | 363.71 |
| P/B ratio | 7.64 | 4.10 |
Profitability
| Metric | ALMR | NAMS |
|---|---|---|
| Gross margin | 56.20% | 92.15% |
| Operating margin | -42.22% | -1002.90% |
| Net margin | -40.18% | -3644.21% |
| ROE | N/A | -41.10% |
| ROIC | -26.95% | -38.70% |
Growth (annualized)
| Metric | ALMR | NAMS |
|---|---|---|
| Total return CAGR (5Y) | N/A | 18.30% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.